In antibody drug discovery it is crucially important how quickly and how many new and good clones are obtained, regardless which platform is employed. In this regard, the Company has access to multiple antibody generation technologies, including the ADLib® system that we developed of our own, and by leveraging the features of each technology in integrated manner, we select the best clone (antibody) in less time. By taking this, we raise the probability of successful antibody generation to put into pipeline. In addition, we have platform technology that supports a wide range of drug discovery processes, not only antibody generation technology, but also technology for protein processing of such as antibody and antigen in high purity, humanization and affinity maturation, and skills and know-how for pharmacological study. We possess sufficient equipment and facility to run all of these works.
The other key element to success is to keep good scientists and researchers. Chiome hires and employs professional people with science and highly developed skills. Also we make efforts to keep our science and technology level high through collaboration with organization and expert people.

• Preparation of Recombinant proteins

  • 

    Expression

  • 

    Recombinant proteins

  • 

    Membrane proteins

  • 

    Purification

• mAb Generation Platform

  • 

    ADLib^®system

  • 

    Animal immjunization

  • 

    B cell cloning

  • 

    Hybridoma

• mAb Engineering

  • 

    Affinity maturation

  • 

    Functional evaluation

  • 

    Multi-specific antibody

  • 

    Lab-scale mAb production

Antibody Generation Technologies

• ADLib^®System

  The ADLib^®system features superior speed to conventional methods and the ability to obtain antibodies that were difficult to obtain by conventional methods.

  In the ADLib® system, genetic recombination is activated in antibodies of DT40 cells to increase the diversity of the antibody protein. (DT40 cells are a cell line prepared from chicken cells.)

  Specific antibodies are then caught like fish with magnetic beads coated with a particular type of antigen.

  Chiome Bioscience holds the exclusive license to this technology developed by RIKEN.

• Learn more

• Hybridoma

  The most common method for producing monoclonal antibodies.

  There are many achievements that antibodies obtained by the hybridoma method became pharmaceutical products.

  Since animals are used, there are limitations to the amount of antigens that can be used and the range of antigens to which the technique can be applied.

• B cell cloning

  After animal immunization, the sequence of the antibody is determined without preparing the hybridoma, so that the target antibody can be generated in a shorter time than the hybridoma method.

  The detection rate of antigen-specific B cells is higher than that of hybridoma method, and the abandon rate is lower.

Patents related to our technologies